Virpax Pharmaceuticals Stock Performance
| VRPX Stock | USD 0.30 0.01 3.23% |
The entity has a beta of -0.43, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Virpax Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Virpax Pharmaceuticals is likely to outperform the market. At this point, Virpax Pharmaceuticals has a negative expected return of -1.08%. Please make sure to validate Virpax Pharmaceuticals' kurtosis, as well as the relationship between the rate of daily change and market facilitation index , to decide if Virpax Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Virpax Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in February 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 1:10 | Last Split Date 2024-03-01 |
1 | Acquisition by Jatinder Dhaliwal of 2500 shares of Virpax Pharmaceuticals at 0.578 subject to Rule 16b-3 | 10/25/2024 |
2 | Virpax Pharmaceuticals, Inc. Announces Pricing of 5.0 Million Public Offering of Common Stock and Pre-Funded Warrants | 11/13/2024 |
3 | Virpax Pharmaceuticals, Inc. Announces Closing of 5.0 Million Public Offering of Common Stock and Pre-Funded Warrants | 11/15/2024 |
4 | Insider Trading | 11/19/2024 |
5 | Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur | 11/22/2024 |
6 | Acquisition by Floyd Eric of 15124 shares of Virpax Pharmaceuticals at 3.43 subject to Rule 16b-3 | 11/26/2024 |
7 | Acquisition by Floyd Eric of 11216 shares of Virpax Pharmaceuticals at 4.62 subject to Rule 16b-3 | 11/29/2024 |
8 | Virpax Pharmaceuticals stock hits 52-week low at 0.36 - Investing.com | 12/06/2024 |
9 | Virpax Pharmaceuticals Welcomes Jay Panis to Board - TipRanks | 12/18/2024 |
10 | Virpax Pharmaceuticals granted Nasdaq listing extension | 01/07/2025 |
11 | Virpax Pharmaceuticals enacts reverse stock split | 01/15/2025 |
| Begin Period Cash Flow | 19 M |
Virpax |
Virpax Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 72.00 in Virpax Pharmaceuticals on October 20, 2024 and sell it today you would lose (42.00) from holding Virpax Pharmaceuticals or give up 58.33% of portfolio value over 90 days. Virpax Pharmaceuticals is currently does not generate positive expected returns and assumes 8.3212% risk (volatility on return distribution) over the 90 days horizon. In different words, 74% of stocks are less volatile than Virpax, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Virpax Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Virpax Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Virpax Pharmaceuticals, and traders can use it to determine the average amount a Virpax Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1294
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VRPX |
Estimated Market Risk
| 8.32 actual daily | 74 74% of assets are less volatile |
Expected Return
| -1.08 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Virpax Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Virpax Pharmaceuticals by adding Virpax Pharmaceuticals to a well-diversified portfolio.
Virpax Pharmaceuticals Fundamentals Growth
Virpax Stock prices reflect investors' perceptions of the future prospects and financial health of Virpax Pharmaceuticals, and Virpax Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Virpax Stock performance.
| Return On Equity | -3.62 | ||||
| Return On Asset | -0.91 | ||||
| Current Valuation | 4.51 M | ||||
| Shares Outstanding | 4.89 M | ||||
| Price To Book | 0.48 X | ||||
| EBITDA | (15.19 M) | ||||
| Net Income | (15.19 M) | ||||
| Cash And Equivalents | 26.06 M | ||||
| Cash Per Share | 2.22 X | ||||
| Total Debt | 7.69 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 11.84 X | ||||
| Book Value Per Share | (0.98) X | ||||
| Cash Flow From Operations | (9.85 M) | ||||
| Earnings Per Share | (13.25) X | ||||
| Market Capitalization | 3.03 M | ||||
| Total Asset | 9.63 M | ||||
| Retained Earnings | (59.54 M) | ||||
| Working Capital | 1.93 M | ||||
About Virpax Pharmaceuticals Performance
Evaluating Virpax Pharmaceuticals' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Virpax Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Virpax Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.42) | (1.49) | |
| Return On Capital Employed | (9.33) | (8.86) | |
| Return On Assets | (1.42) | (1.49) | |
| Return On Equity | (9.03) | (8.58) |
Things to note about Virpax Pharmaceuticals performance evaluation
Checking the ongoing alerts about Virpax Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Virpax Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Virpax Pharmaceuticals generated a negative expected return over the last 90 days | |
| Virpax Pharmaceuticals has high historical volatility and very poor performance | |
| Virpax Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Virpax Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (15.19 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Virpax Pharmaceuticals currently holds about 26.06 M in cash with (9.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Virpax Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Virpax Pharmaceuticals enacts reverse stock split |
- Analyzing Virpax Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Virpax Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Virpax Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Virpax Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Virpax Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Virpax Pharmaceuticals' stock. These opinions can provide insight into Virpax Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Virpax Stock Analysis
When running Virpax Pharmaceuticals' price analysis, check to measure Virpax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virpax Pharmaceuticals is operating at the current time. Most of Virpax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Virpax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virpax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Virpax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.